Non-ablative Oligofractionated Radiation Therapy Before Surgical Transplantation As Radiovaccination

NCT ID: NCT04782752

Last Updated: 2025-02-04

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-04-28
• Study Completion Date: 2025-12-31

Brief Summary

This is a prospective phase I study to determine the safety and feasibility of non-ablative oligofractionated radiation therapy (NORT) before lung transplantation for patients with underlying pulmonary malignancy. We hypothesize that heterogeneous dose distributions could generate a vaccination effect against the tumor by creating anti-tumoral immune response in the body and these patients may be immunized against their tumor which could reduce the risk of cancer recurrence after transplantation despite the anti-rejection medications required for the transplantation.

Detailed Description

This study is designed to deliver short courses of radiation to the pulmonary malignancy followed by resection of the radiated tumor at the time of transplant.

The study is a 3+3 phase 1 study with incremental dose of radiation to determine the maximum tolerated dose (MTD). Dose limiting toxicity (DLT) will be defined as grade 3+ radiation related toxicity. If one DLT is seen, then an additional 3 patients will be treated at the same dose level. If 2 or more DLT are seen at any given dose level, then the previous dose level will be defined as the MTD. A minimum of 3 patients and maximum of 18 patients will be included for the phase 1a. Due to the expected higher radiation risks in patients with end-stage ILD (group 1), these patients will be stratified separately from non-ILD patients (group 2, 3 and 4) during phase 1a. Dose tested are: 3 x 400 cGy, 3 x 600 cGy and 3 x 800 cGy for the ILD cohort and 3 x 800 cGy, 3 x 1000 cGy and 3 x 1200 cGy for the non-ILD cohort.

Once the MTD is determined, patients will proceed to phase 1b using the MTD determined in the phase 1a. ILD and non-ILD patients may have different MTD so two separate phase Ib cohorts will be conducted. A total of 12 patients will be included for each cohort in the phase 1b. The dose distribution will be administered using a standard homogenous dose distribution for tumors ≤2 cm, and an heterogeneous dose distribution for tumors >2 cm.

Conditions

Transplant-Related Lung Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Experimental: Radiation

Patients will be differentiated into 4 groups:

1. Patients with end-stage interstitial lung disease (ILD) and suspected stage I (up to 4 cm) primary lung cancer

2. Patients with end-stage lung disease other than ILD (e.g. emphysema/COPD, cystic fibrosis and pulmonary hypertension) and suspected stage I (up to 4 cm) primary lung cancer

3. Patients with multifocal primary lung cancer (e.g. multifocal adenocarcinoma) in the absence of nodal metastasis and distant metastasis.

4. Patients with isolated pulmonary metastasis in the absence of other sites of malignancy (primary and metastatic).

For this study, different doses will be used for each different group depending on their tumour size. The first 3 patients will start with a dose of 4 Gy, for the ILD group, or 8 Gy, for the non ILD group. The doses are then increased incrementally until the dose limiting toxicity is reached.

Group Type: EXPERIMENTAL

Radiation: Varying Doses of RT

Intervention Type: RADIATION

3+3 radiation dose escalation model to see the maximum tolerated dose

Interventions

Radiation: Varying Doses of RT

3+3 radiation dose escalation model to see the maximum tolerated dose

Intervention Type: RADIATION

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18
• Patients with end-stage lung disease and suspected stage I primary lung cancer based on CT and PET scan not accessible to curative treatment, including surgery and ablative SBRT.
• Patients with multifocal pulmonary malignancy, including multifocal lung adenocarcinoma, not accessible to curative treatment, including surgery and ablative SBRT.
• Patients with isolated metastases in one or both lungs after complete resection of the primary tumor in the absence of other sites of metastatic disease, not accessible to curative treatment, including surgery and ablative SBRT.
• Meet eligibility criteria for lung transplantation with the exception of the underlying malignancy.
• Subjects must be able to understand the potential risks and benefits of the study and must be able to read and provide written, informed consent for the study.

Exclusion Criteria

• Age < 18
• Mediastinal nodes metastasis demonstrated on EBUS-TBNA
• Distant metastasis demonstrated on PET scan or brain imaging.
• Failure to provide informed consent
• Previous thoracic radiation resulting in significant mediastinal or chest wall overlap precluding re-irradiation
• Any other medical condition that, in the opinion of the multidisciplinary team, may interfere with the subject's participation or compliance with the treatment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Marc de Perrot

OTHER

Sponsor Role: lead

Responsible Party

Marc de Perrot

Thoracic Surgeon

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Toronto General Hospital, University Health Network

Toronto, Ontario, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

Marc de Perrot, MD, MSc

Role: CONTACT

marc.deperrot@uhn.ca

416 340-5549

John Cho, MD, PhD

Role: CONTACT

John.Cho@rmp.uhn.ca

416-946-4501 ext. 6513

Facility Contacts

Marc de Perrot, MD, MSc

Role: primary

Marc.dePerrot@uhn.ca

416 340-5549

Fatemeh Zaeimi, MSc

Role: backup

Fatemeh.Zaeimi@uhn.ca

416-340-5686

Other Identifiers

20-5902

Identifier Type: -

Identifier Source: org_study_id